Drug Profile
Mesenchymal stem cell therapy for bronchopulmonary dysplasia - Medipost
Alternative Names: Human umbilical cord blood-derived mesenchymal stem cells - Medipost; PneumostemLatest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator Medipost
- Developer Medipost; Samsung Medical Center
- Class Antidementias; Mesenchymal stem cell therapies; Neural stem cell therapies; Neuroprotectants
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Bronchopulmonary dysplasia
Highest Development Phases
- Phase II Bronchopulmonary dysplasia; Haemorrhage
Most Recent Events
- 22 Jul 2022 Phase-II development in Bronchopulmonary dysplasia (In infants, In children) is ongoing in South Korea (Intratracheal) (NCT04003857)
- 01 Mar 2020 Medipost completes a follow-up phase II clinical trial for Bronchopulmonary dysplasia (In infants) in South Korea (Intratracheal) (NCT01897987)
- 05 Jul 2019 Phase-II clinical trials in Bronchopulmonary dysplasia (In infants, In children) in South Korea (Intratracheal) (NCT04003857)